Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Weighing the Pros and Cons of Neoadjuvant Anti–PD-1 Versus Neoadjuvant Combination Ipilimumab/Nivolumab in Melanoma

Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma

Ongoing immunotherapy trials in neoadjuvant and adjuvant settings and

Frontiers Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma

Timing of pembrolizumab makes a difference in resectable melanoma

Cancers, Free Full-Text

Frontiers Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Novel adjuvant options for cutaneous melanoma - ScienceDirect

Cancers, Free Full-Text

IJMS, Free Full-Text

Advances in targeted therapy and immunotherapy for melanoma (Review)

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial, BMC Cancer

Episode 1: The Role of Adjuvant and Neoadjuvant Therapy in Melanoma

Neoadjuvant Immunotherapy Expands Its Reach in Metastatic Melanoma